Clot Management Devices Market: Rapidly Evolving Industry…… COVID-19….
The global clot
management devices market
size was valued at USD 1.26 billion in
2015 and is further expected to reach a value of USD 1.88 billion by 2024, according to a new report by Grand View
Research, Inc. The market is expected to grow with a CAGR of 4.6% owing to the
key drivers such as increasing prevalence of stroke, Pulmonary Embolism (PE),
Deep Vein Thrombosis (DVT), obesity, growing geriatric population,
technological advancements, and improvement in health insurance coverage &
availability of emergency medical services.
With Covid-19 infections rising globally, the
apprehension regarding a shortage of essential life-saving devices and other
essential medical supplies in order to prevent the spread of this pandemic and
provide optimum care to the infected also widens. In addition, till a
pharmacological treatment is developed, ventilators act as a vital treatment
preference for the COVID-19 patients, who may require critical care. Moreover,
there is an urgent need for a rapid acceleration in the manufacturing process
for a wide range of test-kits (antibody tests, self-administered, and others).
The report will account for Covid19 as a key market contributor.
Globally, the number of people
impacted by PE and DVT, which are collectively known as Venous Thromboembolism
(VTE), is much larger than AIDS, cancer, and road traffic accidents combined
together.
Some of the key industry players are
Medtronic; Boston Scientific Corporation; iVascular; Teleflex; Edwards
Lifesciences; LeMaitre Vascular;Vascular Solutions, Inc.; Straub Medical; and
others. The factors such as technological
advancements, investment in research & development, and compliance with the
regulatory policies are constantly driving the introduction of new clot
management devices and techniques The clot management market is a high risk
segment and the huge costs of clinical trials, new product development, and
marketing activities are expected to act as entry barriers for the industry.
To Request Sample Copy of this report, click the link:
The data published by the U.S. CDC
indicates that stroke is amongst the leading cause of disabilities and is the
fifth leading cause of deaths in the U.S. According to the estimates of CDC, PE
and DVT affect nearly 900,000 people in the U.S. Furthermore, the CDC estimates
also suggest the following:
·
Approximately 60,000 to 100,000
Americans die due to VTE and nearly 10% to 30% of the people are expected to
die within 1 month of their diagnosis
·
Nearly 33% of the people with
VTE will have a recurrence within 10 years
·
In the U.S.,VTE accounts for
over USD 10 billion in medical costs
The various risk factors that lead to VTE
and stroke are classified as high, medium, and other risks. The high risk
factors include hospitalization; spinal, hip, knee, & cancer surgeries; and
inactivity for long time due to various reasons, such as postsurgery, sedentary
lifestyle, etc. The moderate risk factors include age above 60 years, family
history of blood clots, chemotherapy, and excessive use of estrogen-based
medications. The other risk factors include obesity, pregnancy, smoking, and
alcohol consumption.
Further Key Findings from the Study
Suggest:
·
In 2015, percutaneous
thrombectomy devices accounted for the maximum share of over 35%. However, the
neurovascular embolectomy devices segment is expected to register the maximum
CAGR of 6.2% over the forecast period
·
Hospitals accounted for the
maximum share of over 80%, as majority of the stroke, DVT, and PE cases are
treated in emergency and critical care units. The demand for low-risk clot
removal procedures is anticipated to drive the diagnostic center segment.
·
In 2015, North America held the
majority revenue share of over 60.5%. The growing awareness about DVT/PE,
access to advanced healthcare facilities, and presence of robust reimbursement
and regulatory framework are some of the key reasons attributed to the high
market share.
·
Asia Pacific is anticipated to
be the fastest growing region with a CAGR of 5.7% over the forecast period.
·
Some of the key players in the
clot management devices market include Boston Scientific Corporation; Edwards
Lifesciences; Teleflex; Vascular Solutions, Inc.; Straub Medical; LeMaitre
Vascular; Medtronic; iVascular; and others
The clot management devices market is also
anticipated to grow due to technological advancements and the launch of
new-generation thrombectomy devices, such as Penumbra’s AC68 Reperfusion
Catheter; Trevo clot retrieval device manufactured by the Concentric Medical,
Inc.; and EmboTrap II Revascularization Device manufactured by Neuravi.
Stroke
is amongst the leading cause of disabilities and is the fifth leading cause of
deaths in the U.S. according to the CDC. Each year around 130,000 of the U.S.
population dies due to stroke.Ischemic stroke accounts for about 87% of the
cases and occurs when the blood flow to the brain is blocked.Changing
lifestyle, lack of physical exercise, high blood pressure, cholesterol, and
smoking are some of the major factors causing stroke.
Furthermore,
the U.S. FDA approval for marketing of the clot retrieval systems as an initial
therapy for stroke is expected to drive the industry growth. For instance,
Trevo, a clot retrieval device manufactured by the Concentric Medical, Inc. is
a clot removal device and has received FDA approval for marginalizing the
disability associated with stroke.
Have any Query? Ask our Experts:
Grand View Research has segmented the
global clot management devices market by product, end user:
Clot Management Devices Product Outlook (Revenue, USD
Million; 2013 - 2024)
·
Neurovascular Embolectomy
Devices
·
Embolectomy Balloon Catheters
·
Percutaneous Thrombectomy
Devices
·
Catheter-Directed Thrombolysis
(CDT) devices
·
Inferior VenaCava Filters
(IVCF)
Clot Management Devices End-User Outlook (Revenue, USD
Million; 2013 - 2024)
·
Hospitals
·
DiagnosticCenters
About Grand View Research
Grand View Research, Inc. is a U.S.
based market research and consulting company, registered in the State of California
and headquartered in San Francisco. The company provides syndicated research
reports, customized research reports, and consulting services. To help clients
make informed business decisions, we offer market intelligence studies ensuring
relevant and fact-based research across a range of industries, from technology
to chemicals, materials and healthcare.
Comments
Post a Comment